# Centene Corp: financial statements, quarterly

CNC · NYSE · CIK 1071739 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cnc.md) · [Financials](/companies/cnc/financials.md) · [Filings](/companies/cnc/filings.md) · [Insiders](/companies/cnc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cnc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [35.0](/filings/0001071739-24-000200.md) | [35.3 d](/filings/0001071739-26-000049.md) | [36.3](/filings/0001071739-25-000086.md) | [36.0](/filings/0001071739-25-000150.md) | [36.9](/filings/0001071739-25-000183.md) | [36.3 d](/filings/0001071739-26-000049.md) | [42.5](/filings/0001071739-26-000098.md) | [42.5](/filings/0001071739-26-000153.md) | [44.9](/filings/0001071739-25-000183.md) | [44.7 d](/filings/0001071739-26-000049.md) | [44.7](/filings/0001071739-26-000098.md) | [44.4](/filings/0001071739-26-000153.md) |
| Cost of revenue | $bn | [0.9](/filings/0001071739-24-000200.md) | [1.0 d](/filings/0001071739-26-000049.md) | [0.7](/filings/0001071739-25-000086.md) | [0.7](/filings/0001071739-25-000150.md) | [0.7](/filings/0001071739-25-000183.md) | [0.7 d](/filings/0001071739-26-000049.md) | [0.7](/filings/0001071739-26-000098.md) | [0.6](/filings/0001071739-26-000153.md) | [0.7](/filings/0001071739-25-000183.md) | [0.7 d](/filings/0001071739-26-000049.md) | [0.7](/filings/0001071739-26-000098.md) | [0.7](/filings/0001071739-26-000153.md) |
| Gross profit | $bn | [4.6](/filings/0001071739-24-000200.md) | [3.7 d](/filings/0001071739-26-000049.md) | [4.7](/filings/0001071739-25-000086.md) | [4.5](/filings/0001071739-25-000150.md) | [4.0](/filings/0001071739-25-000183.md) | [3.8 d](/filings/0001071739-26-000049.md) | [5.3](/filings/0001071739-26-000098.md) | [3.0](/filings/0001071739-26-000153.md) | [3.3](/filings/0001071739-25-000183.md) | [2.6 d](/filings/0001071739-26-000049.md) | [5.7](/filings/0001071739-26-000098.md) | [4.6](/filings/0001071739-26-000153.md) |
| Selling, general and administrative | $bn | [3.0](/filings/0001071739-24-000200.md) | [3.5 d](/filings/0001071739-26-000049.md) | [3.2](/filings/0001071739-25-000086.md) | [2.9](/filings/0001071739-25-000150.md) | [3.1](/filings/0001071739-25-000183.md) | [3.2 d](/filings/0001071739-26-000049.md) | [3.4](/filings/0001071739-26-000098.md) | [3.0](/filings/0001071739-26-000153.md) | [3.1](/filings/0001071739-25-000183.md) | [3.4 d](/filings/0001071739-26-000049.md) | [3.4](/filings/0001071739-26-000098.md) | [3.1](/filings/0001071739-26-000153.md) |
| Operating income | $bn | [0.7](/filings/0001071739-24-000200.md) | [(0.2) d](/filings/0001071739-26-000049.md) | [1.1](/filings/0001071739-25-000086.md) | [1.2](/filings/0001071739-25-000150.md) | [0.7](/filings/0001071739-25-000183.md) | [0.2 d](/filings/0001071739-26-000049.md) | [1.5](/filings/0001071739-26-000098.md) | [(0.5)](/filings/0001071739-26-000153.md) | [(7.0)](/filings/0001071739-25-000183.md) | [(1.7) d](/filings/0001071739-26-000049.md) | [1.9](/filings/0001071739-26-000098.md) | [1.2](/filings/0001071739-26-000153.md) |
| Interest expense | $bn | [0.2](/filings/0001071739-23-000209.md) | [0.2 d](/filings/0001071739-24-000037.md) | [0.2](/filings/0001071739-24-000097.md) | [0.2](/filings/0001071739-25-000150.md) | [0.2](/filings/0001071739-25-000183.md) | [0.2 d](/filings/0001071739-26-000049.md) | [0.2](/filings/0001071739-26-000098.md) | [0.2](/filings/0001071739-26-000153.md) | [0.2](/filings/0001071739-25-000183.md) | [0.2 d](/filings/0001071739-26-000049.md) | [0.2](/filings/0001071739-26-000098.md) | [0.2](/filings/0001071739-26-000153.md) |
| Income tax | $bn | [0.3](/filings/0001071739-24-000200.md) | [(0.0) d](/filings/0001071739-26-000049.md) | [0.3](/filings/0001071739-25-000086.md) | [0.4](/filings/0001071739-25-000150.md) | [0.2](/filings/0001071739-25-000183.md) | [0.1 d](/filings/0001071739-26-000049.md) | [0.4](/filings/0001071739-26-000098.md) | [0.0](/filings/0001071739-26-000153.md) | [(0.0)](/filings/0001071739-25-000183.md) | [(0.4) d](/filings/0001071739-26-000049.md) | [0.6](/filings/0001071739-26-000098.md) | [0.4](/filings/0001071739-26-000153.md) |
| Net income | $bn | [0.5](/filings/0001071739-24-000200.md) | [0.0 d](/filings/0001071739-26-000049.md) | [1.2](/filings/0001071739-25-000086.md) | [1.1](/filings/0001071739-25-000150.md) | [0.7](/filings/0001071739-25-000183.md) | [0.3 d](/filings/0001071739-26-000049.md) | [1.3](/filings/0001071739-26-000098.md) | [(0.3)](/filings/0001071739-26-000153.md) | [(6.6)](/filings/0001071739-25-000183.md) | [(1.1) d](/filings/0001071739-26-000049.md) | [1.5](/filings/0001071739-26-000098.md) | [1.1](/filings/0001071739-26-000153.md) |
| Diluted EPS | $ per share | [0.87](/filings/0001071739-24-000200.md) | not reported | [2.16](/filings/0001071739-25-000086.md) | [2.16](/filings/0001071739-25-000150.md) | [1.36](/filings/0001071739-25-000183.md) | not reported | [2.63](/filings/0001071739-26-000098.md) | [(0.51)](/filings/0001071739-26-000153.md) | [(13.50)](/filings/0001071739-25-000183.md) | not reported | [3.11](/filings/0001071739-26-000098.md) | [2.19](/filings/0001071739-26-000153.md) |
| Basic EPS | $ per share | [0.87](/filings/0001071739-24-000200.md) | not reported | [2.17](/filings/0001071739-25-000086.md) | [2.16](/filings/0001071739-25-000150.md) | [1.37](/filings/0001071739-25-000183.md) | not reported | [2.64](/filings/0001071739-26-000098.md) | [(0.51)](/filings/0001071739-26-000153.md) | [(13.50)](/filings/0001071739-25-000183.md) | not reported | [3.13](/filings/0001071739-26-000098.md) | [2.21](/filings/0001071739-26-000153.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [18.2](/filings/0001071739-24-000200.md) | [17.2](/filings/0001071739-26-000049.md) | [17.6](/filings/0001071739-25-000086.md) | [17.6](/filings/0001071739-25-000150.md) | [14.6](/filings/0001071739-25-000183.md) | [14.1](/filings/0001071739-26-000049.md) | [14.8](/filings/0001071739-26-000098.md) | [14.5](/filings/0001071739-26-000153.md) | [17.1](/filings/0001071739-25-000183.md) | [17.9](/filings/0001071739-26-000153.md) | [21.3](/filings/0001071739-26-000098.md) | [24.2](/filings/0001071739-26-000153.md) |
| Current assets | $bn | [41.4](/filings/0001071739-23-000209.md) | [40.8](/filings/0001071739-25-000027.md) | [38.4](/filings/0001071739-24-000097.md) | [38.4](/filings/0001071739-24-000157.md) | [37.4](/filings/0001071739-24-000200.md) | [38.0](/filings/0001071739-26-000049.md) | [41.3](/filings/0001071739-25-000086.md) | [40.4](/filings/0001071739-25-000150.md) | [44.1](/filings/0001071739-25-000183.md) | [40.4](/filings/0001071739-26-000153.md) | [45.0](/filings/0001071739-26-000098.md) | [46.7](/filings/0001071739-26-000153.md) |
| Total assets | $bn | [84.4](/filings/0001071739-23-000209.md) | [84.6](/filings/0001071739-25-000027.md) | [82.6](/filings/0001071739-24-000097.md) | [83.1](/filings/0001071739-24-000157.md) | [82.4](/filings/0001071739-24-000200.md) | [82.4](/filings/0001071739-26-000049.md) | [87.0](/filings/0001071739-25-000086.md) | [86.4](/filings/0001071739-25-000150.md) | [82.1](/filings/0001071739-25-000183.md) | [76.7](/filings/0001071739-26-000153.md) | [81.2](/filings/0001071739-26-000098.md) | [83.0](/filings/0001071739-26-000153.md) |
| Current liabilities | $bn | [36.9](/filings/0001071739-23-000209.md) | [36.7](/filings/0001071739-25-000027.md) | [32.8](/filings/0001071739-24-000097.md) | [32.7](/filings/0001071739-24-000157.md) | [34.1](/filings/0001071739-24-000200.md) | [34.3](/filings/0001071739-26-000049.md) | [37.1](/filings/0001071739-25-000086.md) | [36.8](/filings/0001071739-25-000150.md) | [40.6](/filings/0001071739-25-000183.md) | [36.7](/filings/0001071739-26-000153.md) | [40.0](/filings/0001071739-26-000098.md) | [40.8](/filings/0001071739-26-000153.md) |
| Total liabilities | $bn | [59.0](/filings/0001071739-23-000209.md) | [58.7](/filings/0001071739-25-000027.md) | [55.6](/filings/0001071739-24-000097.md) | [55.7](/filings/0001071739-24-000157.md) | [54.9](/filings/0001071739-24-000200.md) | [55.9](/filings/0001071739-26-000049.md) | [59.0](/filings/0001071739-25-000086.md) | [58.9](/filings/0001071739-25-000150.md) | [61.0](/filings/0001071739-25-000183.md) | [56.7](/filings/0001071739-26-000153.md) | [59.6](/filings/0001071739-26-000098.md) | [60.4](/filings/0001071739-26-000153.md) |
| Long-term debt | $bn | [17.9](/filings/0001071739-23-000209.md) | [17.7](/filings/0001071739-25-000027.md) | [17.9](/filings/0001071739-24-000097.md) | [17.5](/filings/0001071739-24-000157.md) | [17.5](/filings/0001071739-24-000200.md) | [18.4](/filings/0001071739-26-000049.md) | [18.3](/filings/0001071739-25-000086.md) | [17.6](/filings/0001071739-25-000150.md) | [17.5](/filings/0001071739-25-000183.md) | [17.4](/filings/0001071739-26-000153.md) | [16.3](/filings/0001071739-26-000098.md) | [16.0](/filings/0001071739-26-000153.md) |
| Current portion of debt | $bn | [0.1](/filings/0001071739-23-000209.md) | [0.1](/filings/0001071739-25-000027.md) | [0.1](/filings/0001071739-24-000097.md) | [0.1](/filings/0001071739-24-000157.md) | [0.1](/filings/0001071739-24-000200.md) | [0.1](/filings/0001071739-26-000049.md) | [0.0](/filings/0001071739-25-000086.md) | [0.0](/filings/0001071739-25-000150.md) | [0.0](/filings/0001071739-25-000183.md) | [0.1](/filings/0001071739-26-000153.md) | [0.1](/filings/0001071739-26-000098.md) | [0.1](/filings/0001071739-26-000153.md) |
| Shareholders' equity | $bn | [25.3](/filings/0001071739-23-000209.md) | [25.8](/filings/0001071739-25-000027.md) | [27.0](/filings/0001071739-24-000097.md) | [27.4](/filings/0001071739-24-000157.md) | [27.3](/filings/0001071739-24-000200.md) | [26.4](/filings/0001071739-26-000049.md) | [27.9](/filings/0001071739-25-000086.md) | [27.4](/filings/0001071739-25-000150.md) | [20.9](/filings/0001071739-25-000183.md) | [20.0](/filings/0001071739-26-000153.md) | [21.4](/filings/0001071739-26-000098.md) | [22.6](/filings/0001071739-26-000153.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [1,021 d](/filings/0001071739-24-000200.md) | [217 d](/filings/0001071739-26-000049.md) | [(456)](/filings/0001071739-25-000086.md) | [2,175 d](/filings/0001071739-25-000150.md) | [(978) d](/filings/0001071739-25-000183.md) | [(587) d](/filings/0001071739-26-000049.md) | [1,510](/filings/0001071739-26-000098.md) | [1,785 d](/filings/0001071739-26-000153.md) | [1,356 d](/filings/0001071739-25-000183.md) | [437 d](/filings/0001071739-26-000049.md) | [4,366](/filings/0001071739-26-000098.md) | [3,590 d](/filings/0001071739-26-000153.md) |
| Capital expenditure | $m | [136 d](/filings/0001071739-24-000200.md) | [223 d](/filings/0001071739-26-000049.md) | [151](/filings/0001071739-25-000086.md) | [186 d](/filings/0001071739-25-000150.md) | [153 d](/filings/0001071739-25-000183.md) | [154 d](/filings/0001071739-26-000049.md) | [135](/filings/0001071739-26-000098.md) | [208 d](/filings/0001071739-26-000153.md) | [211 d](/filings/0001071739-25-000183.md) | [213 d](/filings/0001071739-26-000049.md) | [200](/filings/0001071739-26-000098.md) | [174 d](/filings/0001071739-26-000153.md) |
| Share repurchases | $m | [774 d](/filings/0001071739-24-000200.md) | [31.0 d](/filings/0001071739-26-000049.md) | [151](/filings/0001071739-25-000086.md) | [803 d](/filings/0001071739-25-000150.md) | [1,227 d](/filings/0001071739-25-000183.md) | [943 d](/filings/0001071739-26-000049.md) | [41.0](/filings/0001071739-26-000098.md) | [432 d](/filings/0001071739-26-000153.md) | [0.0 d](/filings/0001071739-25-000183.md) | [2.0 d](/filings/0001071739-26-000049.md) | [29.0](/filings/0001071739-26-000098.md) | [4.0 d](/filings/0001071739-26-000153.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [581](/filings/0001071739-23-000209.md) | [554](/filings/0001071739-24-000097.md) | [550](/filings/0001071739-24-000157.md) | [541](/filings/0001071739-24-000200.md) | [538](/filings/0001071739-25-000086.md) | [531](/filings/0001071739-25-000150.md) | [524](/filings/0001071739-25-000183.md) | [498](/filings/0001071739-26-000098.md) | [494](/filings/0001071739-26-000153.md) | [491](/filings/0001071739-25-000183.md) | [496](/filings/0001071739-26-000098.md) | [498](/filings/0001071739-26-000153.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 493,995,000 at 2026-07-24, from the cover of the [10-Q filed 2026-07-28](/filings/0001071739-26-000153.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.